Investor Presentaiton
USPSTF recommendations are based on the
harms and benefits of each testing modality
Lifetime Colonoscopies and Life-Years Gained
Real-world longitudinal adherence model for simulated cohort
Model Parameters
INVESTOR 20
DAY 23
Life-Years Gained per 1,000 individuals
300
250
200
150
100
50
Colonoscopy
Shield
mts DNA
FIT
0
0
500
1000
1500
Colonoscopies per 1,000 individuals
Screening
CRC
Interval 1-3
Specificity 2,3
Sensitivity2,3
One-Time
Adherence 3-6
Colonoscopy
10 years
95%
86%
38%
FIT
1 year
74%
96%
43%
mtsDNA
3 years
92%
90%
65%
shield™
3
3 years
83%
90%
90%
2000
2500
1. Knudsen AB et al. "Colorectal Cancer Screening: An Updated Decision Analysis." USPSTF [Internet]. 2021. 2. Knudsen AB et al.. Estimation of benefits, burden, and harms of colorectal cancer screening
Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial." JAMA 318, no. 9 (05 2017): 806-15. 5. J.P. Morgan Healthcare Conference 2018. 6. Akram A et al.
"Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting." Clinical Gastroenterology and Hepatology 15,
no. 8 (August 2017): 1265-1270.e1.
GUARDANT strategies: modeling study for the US Preventative Services Task Force. Jama. 2016 Jun 21;315(23):2595-609. 3. Guardant Health Internal Data. 4. Singal AG et al. "Effect of Coloscopy Outreach vs Fecal
110View entire presentation